Previous 10 | Next 10 |
Gainers: Organovo (ONVO) +24%, Iterum Therapeutics (ITRM) +16%, Adagene (ADAG) +14%, Freeline Therapeutics (FRLN) +12%, 180 Life Sciences (ATNF) +12%.Losers: Provention Bio (PRVB) -22%, Eton Pharmaceuticals (ETON) -13%, Lannett (LCI) -12%...
Iterum jumps even as RBC says sulopenem may not be a “shoo-in”Iterum Therapeutics (ITRM) is extending the post-market gains with a ~18.7% rise in early hours in reaction to the FDA decision not to hold an AdCom meeting for the company’s marketing application for...
SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology pla...
CytomX Therapeutics, Inc. (CTMX) Q1 2021 Earnings Conference Call May 06, 2021 5:00 PM ET Company Participants Chau Cheng - Vice President, Investor Relations & Corporate Communications Sean A. McCarthy - President, Chief Executive Officer & Chairman Carlos Campoy - Senior Vice Presid...
Image source: The Motley Fool. CytomX Therapeutics, Inc. (NASDAQ: CTMX) Q1 2021 Earnings Call May 7, 2021 , 3:30 p.m. ET Operator Continue reading For further details see: CytomX Therapeutics, Inc. (CTMX) Q1 2021 Earnings Call Transcript ...
CytomX (CTMX): Q1 GAAP EPS of -$0.26 beats by $0.06.Revenue of $15.97M (-67.8% Y/Y) misses by $2.31M.Press Release For further details see: CytomX EPS beats by $0.06, misses on revenue
SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform...
SOUTH SAN FRANCISCO, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody ® tec...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead The second quarter is off to a blazing start with the S&P 500 Index pushing above 4,000 on the heels of President Bi...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
News, Short Squeeze, Breakout and More Instantly...
CytomX Therapeutics Inc. Company Name:
CTMX Stock Symbol:
NASDAQ Market:
CytomX Therapeutics Inc. Website:
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a firesid...
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024. “Chris has mad...